Hydroxyurea Treatment for Pediatric Patients with Sickle Cell Disease
Abstract views: 66
/ 
PDF downloads: 26
DOI:
https://doi.org/10.61705/cdjnkb14Abstract
The significant causes of morbidity and mortality in sickle cell disease are the acute and long-term consequences of vaso-occlusion and hemolysis, many of which cannot be reversed (e.g., tissue infarction, vasculopathy). This review discusses hydroxyurea therapy in sickle cell disease, including the mechanism of action and adverse effects.
References
Albohassan H, Ammen M, Alomran AA, Bu Shehab H, Al Sakkak H, Al Bohassan A. Impact of Hydroxyurea Therapy in Reducing Pain Crises, Hospital Admissions, and Length of Stay Among Sickle Cell Patients in the Eastern Region of Saudi Arabia. Cureus. 2022 Nov 15;14(11):e31527. doi: 10.7759/cureus.31527. PMID: 36540486; PMCID: PMC9754745.
Zahran AM, Elsayh KI, Saad K, Embaby MM, Youssef MAM, Abdel-Raheem YF, Sror SM, Galal SM, Hetta HF, Aboul-Khair MD, Alblihed MA, Elhoufey A. Circulating Microparticles in Children With Sickle Cell Anemia in a Tertiary Center in Upper Egypt. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619828839. doi: 10.1177/1076029619828839. PMID: 30740989; PMCID: PMC6714952.
Zahran AM, Elsayh KI, Saad K, Embaby M, Ali AM. Regulatory B cells (CD19(+)CD38(hi)CD24(hi)) in alloimmunized and non-alloimmunized children with β-thalassemia major. Blood Cells Mol Dis. 2016 Mar;57:91-6. doi: 10.1016/j.bcmd.2016.01.005. Epub 2016 Jan 20. PMID: 26852663.
Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014 Jun;30(2):91-6. doi: 10.1007/s12288-013-0261-4. Epub 2013 May 24. PMID: 24839362; PMCID: PMC4022916.
Zahran AM, Saad K, Elsayh KI, Alblihed MA. Characterization of circulating CD4+ CD8+ double positive and CD4- CD8- double negative T-lymphocyte in children with β-thalassemia major. Int J Hematol. 2017 Mar;105(3):265-271. doi: 10.1007/s12185-016-2140-x. Epub 2016 Nov 15. PMID: 27848181.
Pandey A, Kaur H, Borah S, Khargekar N, Karra VK, Adhikari T, Jain D, Madkaikar M. A systematic review on hydroxyurea therapy for sickle cell disease in India. Indian J Med Res. 2022 Aug;156(2):299-311. doi: 10.4103/ijmr.ijmr_3447_21. PMID: 36629190; PMCID: PMC10057355.
Elsayh KI, Saad K, Hetta HF, Youssef MAM, Embaby MM, Mohamed IL, Abdel-Aziz SM, Zahran ZAM, Elhoufey A, Ghandour AMA, Zahran AM. Impact of hydroxyurea on lymphocyte subsets in children with sickle cell anemia. Pediatr Res. 2023 Mar;93(4):918-923. doi: 10.1038/s41390-021-01892-x. Epub 2021 Dec 11. PMID: 34897281..
Zahran AM, Saad K, Elsayh KI, Khalaf SM, Mahmoud KH, Elhoufey A, Hetta HF. Regulatory T-cell phenotypes in children with sickle cell disease. Pediatr Res. 2022 Apr;91(5):1203-1206. doi: 10.1038/s41390-021-01627-y. Epub 2021 Jun 18. PMID: 34145401.
Zahran AM, Nafady A, Saad K, Hetta HF, Abdallah AM, Abdel-Aziz SM, Embaby MM, Abo Elgheet AM, Darwish SF, Abo-Elela MGM, Elhoufey A, Elsayh KI. Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029619895111. doi: 10.1177/1076029619895111. PMID: 31942811; PMCID: PMC7098201.
Mbaezue RN, Okafor AT, Nkwocha BI, Ibeneme CN, Opara AC, Akahara DE, Okobi OE. The Effectiveness of Common Interventions in the Management of Sickle Cell Disease in Primary Care Settings: A Review. Cureus. 2023 Sep 6;15(9):e44780. doi: 10.7759/cureus.44780. PMID: 37809245; PMCID: PMC10558056.
Additional Files
Published
Issue
Section
License
Copyright (c) 2023 International Journal of Medical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
